[1]Dohner H., Estey E., Grimwade D. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424-447. 4
[2]Willekens C., Blanchet O., Renneville A. Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial. Haematologica. 2016;101:328-335. 3
[3]Abdelhamid E., Preudhomme C., Helevaut N. Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia. Leuk Res. 2012;36:316-323. 3
[4]Jourdan E., Boissel N., Chevret S. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood. 2013;121:2213-2223. 12
[5]Ivey A., Hills R.K., Simpson M.A. Assessment of minimal residual disease in standard-risk AML. N Engl J Med. 2016;374:422-433. 5
[6]Balsat M., Renneville A., Thomas X. Postinduction minimal residual disease predicts outcome and benefit from allogeneic stem cell transplantation in acute myeloid leukemia with NPM1 mutation: a study by the acute leukemia French association group. J Clin Oncol. 2017;35:185-193. 2
[7]van Stijn A., Kok A., van Stalborch M.A. Minimal residual disease cells in AML patients have an apoptosis-sensitive protein profile. Leukemia. 2004;18:875-877. 4
[8]Terwijn M., van Putten W.L., Kelder A. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol. 2013;31:3889-3897. 31
[9]Terwijn M., Zeijlemaker W., Kelder A. Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia. PLoS One. 2014;9:e107587. 9
[10]Cilloni D., Renneville A., Hermitte F. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol. 2009;27:5195-5201. 31
[11]Jongen-Lavrencic M., Grob T., Hanekamp D. Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med. 2018;378:1189-1199. 13
[12]Jaiswal S., Fontanillas P., Flannick J. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371:2488-2498. 26
[13]Lambert J., Nibourel O., Pautas C. MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin. Oncotarget. 2014;5:6280-6288. 15
[14]Thol F., Kolking B., Damm F. Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations. Genes Chromosomes Cancer. 2012;51:689-695. 7
[15]Schuurhuis G.J., Heuser M., Freeman S. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018;131:1275-1291. 12
[16]Candoni A., De Marchi F., Zannier M.E. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission. Leuk Res. 2017;63:22-27.
[17]Dillon R, Hills RK, Freeman SD, et al. Molecular MRD status and outcome after transplantation in NPM1 mutated AML: results from the UK NCRI AML17 study. Blood 2020. pii: blood.2019002959. doi: 10.1182/blood.2019002959 [Epub ahead of print].
[18]Tsirigotis P., Byrne M., Schmid C. Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT. Bone Marrow Transplant. 2016;51:1431-1438. 11
[19]Dulery R., Nibourel O., Gauthier J. Impact of Wilms’ tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AML. Bone Marrow Transplant. 2017;52:539-543. 4
[20]Castaigne S., Pautas C., Terre C. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379:1508-1516. 9825